QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.127183v1 jpet.107.127183v2 323/2/469    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foster, C. A. Articles by Billich, A. Search for Related Content PubMed PubMed Citation Articles by Foster, C. A. Articles by Billich, A.

INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

Novartis Institutes for BioMedical Research, Vienna, Austria (C.A.F., L.M.H., B.B., R.R., M.S., A.B.); Novartis Institutes for BioMedical Research, Basel, Switzerland (P.C.H., C.B.); Novartis Pharma AG, Basel, Switzerland (A.S.); and Novartis Pharma AG, Muttenz, Switzerland (E.P.)

FTY720 [2-amino-2-[2-(4-octylphenyl) ethyl]propane-1,3-diol hydrochloride] is an oral sphingosine-1-phosphate receptor modulator under development for the treatment of multiple sclerosis (MS). The drug is phosphorylated in vivo by sphingosine kinase 2 to its bioactive form, FTY720-P. Although treatment with FTY720 is accompanied by a reduction of the peripheral lymphocyte count, its efficacy in MS and experimental autoimmune encephalomyelitis (EAE) may be due to additional, direct effects in the central nervous system (CNS). We now show that FTY720 localizes to the CNS white matter, preferentially along myelin sheaths. Brain trough levels of FTY720 and FTY720-P in rat EAE are of the same magnitude and dose dependently increase; they are in the range of 40 to 540 ng/g in the brain tissue at efficacious doses and exceed blood concentrations severalfold. In a rat model of chronic EAE, prolonged treatment with 0.03 mg/kg was efficacious, but limiting the dosing period failed to prevent EAE despite a significant decrease in blood lymphocytes. FTY720 effectiveness is likely due to a culmination of mechanisms involving reduction of autoreactive T cells, neuroprotective influence of FTY720-P in the CNS, and inhibition of inflammatory mediators in the brain.

Address correspondence to: Dr. Andreas Billich, Novartis Institutes for BioMedical Research, Brunner Strasse 59, A-1235 Vienna, Austria. E-mail: andreas.billich{at}novartis.com

This article has been cited by other articles:

				V. E. Miron, J. A. Hall, T. E. Kennedy, B. Soliven, and J. P. Antel Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod Am. J. Pathol., October 1, 2008; 173(4): 1143 - 1152. [Abstract] [Full Text] [PDF]

				D. Wheeler, V. V. R. Bandaru, P. A. Calabresi, A. Nath, and N. J. Haughey A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis Brain, September 4, 2008; (2008) awn190v1. [Abstract] [Full Text] [PDF]